Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Drops By 29.5%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the target of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 4,970,000 shares, a drop of 29.5% from the October 31st total of 7,050,000 shares. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is currently 2.4 days.

Wall Street Analysts Forecast Growth

ZNTL has been the topic of several recent research reports. Oppenheimer reissued an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research note on Monday, August 12th. Guggenheim reduced their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Kennedy Capital Management LLC acquired a new position in shares of Zentalis Pharmaceuticals in the first quarter worth $189,000. SG Americas Securities LLC purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth about $58,000. Values First Advisors Inc. increased its holdings in Zentalis Pharmaceuticals by 5.4% during the 2nd quarter. Values First Advisors Inc. now owns 74,925 shares of the company’s stock worth $306,000 after purchasing an additional 3,859 shares during the period. Bank of New York Mellon Corp raised its position in Zentalis Pharmaceuticals by 15.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 333,719 shares of the company’s stock valued at $1,365,000 after purchasing an additional 43,839 shares in the last quarter. Finally, Anfield Capital Management LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $40,000.

Zentalis Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ ZNTL opened at $3.61 on Friday. The business’s 50 day moving average is $3.38 and its two-hundred day moving average is $4.93. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07. The firm has a market cap of $257.25 million, a price-to-earnings ratio of -1.48 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.